Radio-Wave Heating of Iron Oxide Nanoparticles Can Regulate Plasma Glucose in Mice

Stanley, Sarah; Gagner, Jennifer E.; Damanpour, Shadi; Yoshida, Mitsukuni; Dordick, Jonathan S.; Friedman, Jeffrey M.

doi:10.1126/science.1216753

Cited by 445 publications

(406 citation statements)

References 32 publications

Supporting

Mentioning

394

Contrasting

Unclassified

Order By: Relevance

“…Our results suggest that such an approach could be effective at young and old age. Also magnetic beads can be used to improve the selective delivery of agents at the tumor site that improves anti-tumor responses or kill tumor cells directly, with minor side effects on normal tissues [48].…”

Section: Discussionmentioning

confidence: 99%

Cancer Vaccination at Older Age

Gravekamp

2013

Cancer and Aging

View full text Add to dashboard Cite

Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness. This is caused by various age-related changes of the immune system, such as lack of naïve T cells, defects in activation pathways of T cells and antigen-presenting cells, and age-related changes in the tumor microenvironment. Natural killer, natural killer T cells, and γδT cells of the innate immune system also change with age but these responses may be more susceptible for improvement than adaptive immune responses at older age. This chapter compares various studies involving adaptive and innate immune responses in elderly and cancer patients, as well as cancer vaccination at young and old age. Finally, potential new directions in cancer vaccination at older age are discussed. With the current rise of the elderly population, cancer is becoming an increasingly frequent disease and cause of death. From 2010 to 2030, the total projected cancer incidence in the United States for older adults will increase by approximately 67% [1]. Indeed, metastatic cancer has surpassed heart disease as the primary cause of death in people younger than age 85 [2]. Therefore, in spite of some improvements in prevention and treatment, metastatic cancer is now the most frequent cause of death in the elderly, with co-morbid conditions complicating further treatment. When metastatic, cancer often needs aggressive, second-line treatment, for which there are few options. This is particularly challenging for frail, elderly cancer patients in which co-morbidity plays an important role. Immunotherapy may be our best and most benign option for preventing or curing metastatic cancer in such patients. Unfortunately, cancer immunotherapy is less effective at old than at young age, due to T cell unresponsiveness, especially in the tumor microenvironment (TME) [3,4]. Various age-related changes of the immune system, such as lack of naïve T cells, defects in activation pathways of T cells and antigen-presenting cells (APC), and immune suppression in the TME contribute to T cell unresponsiveness at older age [4].

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer Vaccination at Older Age

Gravekamp

2013

Cancer and Aging

View full text Add to dashboard Cite

show abstract

“…Além da tendência de apropriação por parte de outros ramos, o tipo de autoria dos artigos também reflete a construção -ainda em curso -do conhecimento científico na área. Desta forma, embora a nanotecnologia comece a tomar um papel importante no cotidiano das práticas científicas, conforme anteriormente mencionado, ao intitular ou resumir seu artigo, os pesquisadores progressivamente passam a dar preferência a termos mais específicos, como nanotubos (Sfeir et al, 2004), nanopartículas (Stanley et al, 2012), nanoestruturas (Arslan et al, 2005), nanofios (Reches, Gazid, 2003), etc.…”

Section: Figura 2 Artigos Científicos Sobre Nanotecnologia Publicadounclassified

“…Destacaram-se, ainda, as aplicações biomédicas, voltadas para diagnóstico por imagens, liberação controlada de medicamentos (Suresh, 2001;Dzenis, 2004;Marshall, 2005;Walt, 2005, Lavine, 2005a, Aldaye et al, 2008Ray, 2010;Brongersma, Shalaev, 2010;Service, 2011;Thodey, Smolke, 2011;Stanley et al, 2012). No entanto, a tônica foi o uso da nanotecnologia na terapia do câncer (Kaiser, 2004;Service, 2004a;Service, 2005b;Walt, 2005;Lavine, 2005b;Holden, 2009;Brongersma, Shalaev, 2010;Service, 2011).…”

Section: Figura 6 áReas De Aplicação Nanotecnológicaunclassified

Nanotecnociência e Humanidade

Pyrrho¹,

Schrram²

2016

View full text Add to dashboard Cite

A navegação consulta e descarregamento dos títulos inseridos nas Bibliotecas Digitais UC Digitalis, UC Pombalina e UC Impactum, pressupõem a aceitação plena e sem reservas dos Termos e Condições de Uso destas Bibliotecas Digitais, disponíveis em https://digitalis.uc.pt/pt-pt/termos.Conforme exposto nos referidos Termos e Condições de Uso, o descarregamento de títulos de acesso restrito requer uma licença válida de autorização devendo o utilizador aceder ao(s) documento(s) a partir de um endereço de IP da instituição detentora da supramencionada licença.Ao utilizador é apenas permitido o descarregamento para uso pessoal, pelo que o emprego do(s) título(s) descarregado(s) para outro fim, designadamente comercial, carece de autorização do respetivo autor ou editor da obra. Na medida em que todas as obras da UC Digitalis se encontram protegidas pelo Código do Direito de Autor e Direitos Conexos e demais legislação aplicável, toda a cópia, parcial ou total, deste documento, nos casos em que é legalmente admitida, deverá conter ou fazer-se acompanhar por este aviso.

show abstract

“…The latter harbors a synthetic promoter sequence with cognate DNA response elements (CRE, SRE, NFAT-RE) that recruit signaling pathway-specific transcription factors. Thus far, synthetic GPCRbased gene control systems have been engineered that respond to metabolites, hormones, and drug ligands, including luteinizing hormone (Kemmer et al 2011), histamine (Ausländer et al 2014b), dopamine (Rössger et al 2013a), and guanabenz (Ye et al 2013), in addition to other signals, such as pH changes (Ausländer et al 2014a), heat (Stanley et al 2012), and blue light (Ye et al 2011). The orthogonal usage of multiple GPCRs in individual cells is impeded if they use the same signaling pathway.…”

Section: Transcriptional Gene Switchesmentioning

confidence: 99%